Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.39 USD
Change Today -0.15 / -2.71%
Volume 83.8K
ADMP On Other Exchanges
As of 5:20 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

adamis pharmaceuticals corp (ADMP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $7.26
52 Week Low
08/15/14 - $2.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

adamis pharmaceuticals corp (ADMP) Related Businessweek News

No Related Businessweek News Found

adamis pharmaceuticals corp (ADMP) Details

Adamis Pharmaceuticals Corporation, a biopharmaceutical company, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology. Its specialty pharmaceutical division has four products in its pipeline, including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease (COPD); and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. The company’s biotechnology division focuses on the development of therapeutic vaccine product candidates and cancer drugs for patients with unmet medical needs in the global cancer markets. Its four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer; and three drugs comprise APC-100, APC-200, and APC-300 for the treatment of prostate cancer. The company is headquartered in San Diego, California.

adamis pharmaceuticals corp (ADMP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $625.2K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $247.7K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $287.7K
Compensation as of Fiscal Year 2014.

adamis pharmaceuticals corp (ADMP) Key Developments

Adamis Pharmaceuticals Corporation, Board Meeting, Mar 05, 2015

Adamis Pharmaceuticals Corporation, Board Meeting, Mar 05, 2015.

Adamis Pharmaceuticals Corporation Announces Positive Pharmacokinetic Study Results for its Dry Powder Inhaler Product

Adamis Pharmaceuticals Corporation announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. The study was a Phase I PK study comparing the bioavailability of Adamis' APC-5000 Dry Powder Inhaler (DPI) to GlaxoSmithKline's Advair Diskus DPI. This PK study was designed as an open-label, randomized, single-dose, 4 period (2 sequence, 2 treatment, fully replicated) crossover relative bioavailability study comparing APC-5000 (Fluticasone Propionate (FP) 186 µg and Salmeterol Xinafoate (SX) 44.7 µg; 3 inhalations; total dose 558/134.1 µg FP/SX) and Advair Diskus 250/50 µg (3 inhalations; total dose 750/150 µg FP/SX). Sixteen healthy male and female subjects who met the study inclusion criteria were enrolled into the study. The study involved a screening period and four treatment periods separated by four days. After completion of screening procedures, subjects were randomized to receive two doses of each Test and Reference product in four treatment periods. All sixteen subjects completed the study. APC-5000 utilizes the patented Taper DPI inhaler device which, in this case, has been developed to eliminate the need for complex powder treatments and additive substances such as lactose, i.e. there is no need for excipients. It was also developed to deliver a higher percentage of fine particles to the airways with better delivery efficiency, and by doing so, decrease the drug deposition in the throat and mouth. Because of this increased efficiency, less amount of drug is loaded into the device thereby reducing the amount of drug given to the patient while still maintaining the same theoretical therapeutic dose. The study results confirm that systemic exposure to the drugs FP and SX is reduced after treatment with APC-5000, as compared to Advair Diskus, thereby potentially increasing the overall safety of the product.

Adamis Pharmaceuticals Corporation Announces Positive Pharmacokinetic Study Results for its Beclomethasone Dipropionate HFA Product

Adamis Pharmaceuticals Corporation announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose, four-way crossover PK study comparing Adamis' APC-1000 (Beclomethasone Dipropionate HFA, ["BDP"] 80 mcg Inhalation Aerosol) to Teva Respiratory, LLC's Qvar (Beclomethasone Dipropionate HFA, 80 mcg Inhalation Aerosol). Twenty-two healthy male and female subjects who met the study inclusion criteria were enrolled. The study involved a screening period before randomization and four treatment periods each separated by a minimum of three days. Both Inhalation Aerosols were administered to each subject for a total dose of 320 mcg BDP (4 inhalations). Twenty-one subjects completed the study. One subject was withdrawn due to non-compliance. The purpose of this PK study was to compare the bioavailability of APC-1000 to Qvar. The results show the extent of absorption of APC-1000 to be equivalent to Qvar.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMP:US $5.39 USD -0.15

ADMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Delcath Systems Inc $1.01 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation ADMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADAMIS PHARMACEUTICALS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at